Biodexa (NASDAQ: BDRX) director reports detailed stock option holdings

Rhea-AI Filing Summary

Biodexa Pharmaceuticals Plc director Stephen Barry Parker filed an initial statement of ownership showing holdings of a stock option over 576 American Depositary Shares. The option has an exercise price of $475.0000 per ADS and expires on January 23, 2034.

The shares underlying this option vest over four years, with 25% vesting on the one-year anniversary of grant and 6.25% vesting every three months thereafter, subject to his continued service. Each American Depositary Share represents 100,000 ordinary shares of Biodexa.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Parker Stephen Barry

(Last) (First) (Middle)

C/O BIODEXA PHARMACEUTICALS PLC

1 CASPIAN POINT, CASPIAN WAY

(Street)

CARDIFF CF104DQ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Biodexa Pharmaceuticals Plc [ BDRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	01/23/2034	American Depositary Shares(2)	576	$475(3)	D

Explanation of Responses:

1. The shares underlying this option vest over a four-year period with (i) 25% vesting on the one-year anniversary of grant, and (ii) 6.25% vesting every three months thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

2. Each American Depositary Share represents 100,000 ordinary shares, nominal value PS0.000001 per share, of the Issuer.

3. The exercise price for this option is denominated in British pounds sterling at a price of GBP 373.936 per American Depositary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.2703. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.

Remarks:

Exhibit 24.1 -- Power of Attorney

	/s/ Fiona Mary Powell, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What did Stephen Barry Parker report in his Form 3 for BDRX?

Stephen Barry Parker reported holding a stock option over 576 American Depositary Shares of Biodexa Pharmaceuticals Plc. The Form 3 is an initial ownership filing, showing his existing derivative position rather than a new market trade.

What are the key terms of Stephen Barry Parker’s stock option in BDRX?

The stock option covers 576 American Depositary Shares with a $475.0000 exercise price per ADS. It expires on January 23, 2034 and represents a right to buy shares rather than current share ownership.

How does Stephen Barry Parker’s BDRX option vest over time?

The option vests over four years. Twenty-five percent vests on the one-year anniversary of grant, and an additional 6.25% vests every three months afterward, contingent on his continued service through each vesting date.

Does Stephen Barry Parker’s Form 3 for BDRX show any share purchases or sales?

No, the Form 3 reflects an existing stock option holding, not a new purchase or sale. It lists a right to buy 576 American Depositary Shares, serving as an initial disclosure of derivative ownership.

How many ordinary shares does each Biodexa ADS in Stephen Barry Parker’s option represent?

Each American Depositary Share represents 100,000 ordinary shares of Biodexa Pharmaceuticals Plc. Parker’s option is therefore tied to ADS units, which bundle underlying ordinary shares for trading convenience in U.S. markets.

In what currency is the exercise price of Stephen Barry Parker’s BDRX option set?

The exercise price is denominated in British pounds sterling at GBP 373.936 per ADS. It is reported as $475.0000 using a GBP 1.00 to USD 1.2703 conversion rate, though the actual obligation is in pounds.